Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report.

ABSTRACT:

Rationale

Chimeric antigen receptor-modified T-cell (CART) therapy has revolutionized the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). However, the capacity of CART therapy has not yet been fully elucidated.

Patient concerns

An 18-year-old Chinese male patient presented with multiple firm masses on the skin all over his body following regular chemotherapy.

Diagnoses

Bone marrow smear and skin biopsy confirmed that it was a bone marrow and skin relapse from the initial B-cell ALL.

Interventions

CD19 CART-cell therapy was performed to manage the bone marrow and skin of the relapsed B-cell ALL.

Outcomes

During CART-cell therapy, cytokine release syndrome and central nervous encephalopathy occurred. Eventually,

SUBMITTER: Yang M 

PROVIDER: S-EPMC7440224 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature